Latest Breaking News On - Thomas biegi - Page 1 : comparemela.com

MorphoSys AG Reports First Quarter 2024 Financial Results

MorphoSys AG Reports First Quarter 2024 Financial Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMonjuvi minjuviDennis riedlEamonn nolanJulia neugebauerThomas biegiJean paul kressXencor incGroup revenuesExchange commissionGerman federal financial supervisory authority the bafinDevelopment rd expensesDrug administrationConstellation pharmaceuticals incAdditional groupShare of loss associates

MorphoSys AG Reports First Quarter 2024 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 20.

United statesMonjuvi minjuviJulia neugebauerEamonn nolanJean paul kressThomas biegiDistribution servicesIncyte corporationMorphosys group key figuresCorporate affairsDrug administrationEuropean medicines agencyAmerican society of clinical oncologyGerman federal financial supervisory authority the bafinLymphoma societyCompany annual report on form

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

EQS-News: MorphoSys AG / Key word: Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting.

United statesKaitlyn nealyThomas biegiJulia neugebauerAmerican society of clinical oncologyCorporate affairsLymphoma societyConstellation pharmaceuticals incSys to present new phaseOral presentationClinical oncologyEfficacy dataCombination with ruxolitinibPatients withAdvanced solid tumorsVice president

MorphoSys AG: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

MorphoSys AG: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesKaitlyn nealyDennis riedlJulia neugebauerThomas biegiLymphoma societyAmerican society of clinical oncologyCorporate affairsConstellation pharmaceuticals incClinical oncologyEfficacy dataCombination with ruxolitinibPatients withAdvanced solid tumorsVice presidentGlobal head

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation

EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April.

United statesKaitlyn nealyJulia neugebauerThomas biegiAmerican society of clinical oncologyLymphoma societyConstellation pharmaceuticals incDistribution servicesCorporate affairsSys to present new phaseOral presentationClinical oncologyEfficacy dataCombination with ruxolitinibPatients withAdvanced solid tumors